Related Experiment Video

Updated: Jun 21, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting the PI3K/AKT pathway for the treatment of prostate cancer

Debashis Sarker1, Alison H M Reid, Timothy A Yap

  • 1Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 30, 2009
PubMed

Insights

Targeting the phosphatidylinositol 3-kinase pathway offers new hope for advanced prostate cancer. Careful selection of therapies and biomarkers is crucial for effective treatment of castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer management, particularly castration-resistant prostate cancer, remains challenging despite scientific progress.
  • The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in prostate cancer development.
  • Understanding PI3K pathway's role is key to improving treatment strategies.

Purpose of the Study:

  • To review the role of the PI3K pathway in prostate cancer pathogenesis.
  • To discuss the therapeutic implications of targeting the PI3K pathway.
  • To emphasize the importance of biomarker selection for PI3K-targeted therapies.

Main Methods:

  • Literature review of studies on PI3K pathway in prostate cancer.
  • Analysis of current and emerging therapeutic strategies targeting PI3K.
  • Evaluation of the role of biomarkers in treatment selection.

Main Results:

  • The PI3K pathway is a significant driver in prostate cancer.
  • Targeting the PI3K pathway shows promise for castration-resistant disease.
  • Biomarker-guided selection of agents and combinations is essential.

Conclusions:

  • The PI3K pathway is a critical target for prostate cancer therapy.
  • Personalized approaches using predictive and pharmacodynamic biomarkers are vital for successful PI3K-targeted treatment.
  • Further research into optimal therapeutic combinations and biomarker strategies is warranted.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...